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Abstract
Excessive inflammatory responses in the surgical patient may result in cellular hypo-respon-
siveness, which is associated with an increased risk of secondary infection and death.
microRNAs (miRNAs), such as miR-155, are powerful regulators of inflammatory signalling
pathways including nuclear factor κB (NFκB). Our objective was to determine the effect of
IκK-16, a selective blocker of inhibitor of kappa-B kinase (IκK), on miRNA expression and
the monocyte inflammatory response. In a model of endotoxin tolerance using primary
human monocytes, impaired monocytes had decreased p65 expression with suppressed
TNF-α and IL-10 production (P < 0.05). miR-155 and miR-138 levels were significantly upre-
gulated at 17 h in the impaired monocyte (P < 0.05). Notably, IκK-16 decreased miR-155
expression with a corresponding dose-dependent decrease in TNF-α and IL-10 production
(P < 0.05), and impaired monocyte function was associated with increased miR-155 and
miR-138 expression. In the context of IκK-16 inhibition, miR-155 mimics increased TNF-α
production, while miR-155 antagomirs decreased both TNF-α and IL-10 production. These
data demonstrate that IκK-16 treatment attenuates the monocyte inflammatory response,
which may occur through a miR-155-mediated mechanism, and that IκK-16 is a promising
approach to limit the magnitude of an excessive innate inflammatory response to LPS.
Introduction
A frequent complication in patients following trauma, major surgery, or sepsis is secondary
infection [1]. Impaired pathogen clearance may occur due to defective host defense mecha-
nisms as a result of such a significant physiological insult to the body [2]. Genomic, transcrip-
tomic, and proteomic studies in trauma patients show that the magnitude of the immunologic
response after an insult, such as trauma, correlates with a higher risk of subsequent complica-
tions [3, 4]. Impaired monocyte function is one facet of immune dysregulation that continues
to be recognized as a central tenant of trauma- or sepsis-related immunosuppression [5, 6].
However, efforts to pharmacologically modulate this response have failed to consistently
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IκK-16 is a new therapy recently studied in animal models of sepsis and shock [9, 10] that
reduces nuclear factor-κB (NFκB) activation by selectively blocking inhibitor of kappa-B
kinase (IκK), and thus decrease the magnitude of the pro-inflammatory response. The benefi-
cial effects of IκK-16 have included decreased lung injury, renal dysfunction, and cardiac fail-
ure; however, this treatment has not been applied to humans [11, 12]. A better understanding
of how IκK-16 affects intracellular mechanisms in human leukocytes is required.
microRNAs (miRNAs) are increasingly recognized as important regulators of immune
function. These small non-coding RNAs are stimulated and released into the intracellular and
extracellular environment by various triggers such as pathogen- and danger-associated molec-
ular patterns (DAMPs and PAMPs). The stability of miRNAs has placed miR-based biomarker
research at the forefront of contemporary cancer and sepsis-related academic inquiries [13,
14]. One of the most commonly studied miRNAs is miR-155, which is expressed in myeloid
cells and is upregulated in response to lipopolysaccharide (LPS) stimulation to toll-like recep-
tor (TLR)-4 receptors [15]. miR-155 inhibits the translation of suppressor of cytokine signal-
ing-1 (SOCS1) and Src-homology region 2 domain-containing phosphatase-1 (SHP-1)
mRNA, among other target genes, into functional proteins. As a result, this post-transcrip-
tional modification releases the suppression on signaling pathways, resulting in the promotion
of the pro-inflammatory response [16, 17].
Our group has previously demonstrated the important role and regulation of miR-155 in
immune dysfunction during hypothermia using a model based on primary human monocytes.
In the current study, we have adopted a model of impaired monocyte function, or endotoxin
tolerance, which is representative of the cellular hypo-responsiveness observed in some surgi-
cal patients [18, 19]. Our initial data demonstrated that miRNA-155 was consistently upregu-
lated in the impaired monocyte. We hypothesized that IκK-16 would decrease the expression
of miR-155 and decrease monocyte cytokine production in response to LPS.
Materials and methods
Subjects and monocyte isolation
This study was approved by the University of Louisville Institutional Review Board. Blood
from healthy volunteers was collected in EDTA vacutainers (Becton Dickinson, Franklin
Lakes, NJ). Anti-inflammatory medication, or the presence of acute illness or chronic disease,
was cause for exclusion.
Human Whole Blood CD14 Microbeads (Miltenyi Biotec, Auburn, CA) were used for posi-
tive selection of monocytes according to the manufacturer’s instructions. Monocytes were
>95% purified as determined by flow cytometry and were manually counted with Trypan Blue
staining to ensure that cells were>95% viable. Monocytes were cultured in RPMI 1640 (Sigma
Aldrich, St Louis, MO) and supplemented with 10% fetal bovine serum, L-glutamine, and anti-
biotic/antimycotic agents (Thermo Fisher Scientific, Waltham, MA) in an incubator with 5%
CO2 at 37˚C. All cultures occurred in cell suspension using 50 mL polypropylene tubes con-
taining 1 x 106 cells per condition. In the model of endotoxin tolerance, following isolation
and 1 h of rest, monocytes were treated for 16 h with either media only (naïve control) or 10
ng/mL of LPS (impaired) (Escherichia coli 0111:B4; Sigma Aldrich, St. Louis, MO). At 17 h fol-
lowing isolation, monocytes were centrifuged, washed, counted, and re-suspended in fresh
media at a concentration of 0.5 x 106 per mL. Cells were then stimulated with a 100 ng/mL LPS
challenge to determine the inflammatory response. At the indicated time points, supernatant
was collected and stored at -80˚C until further analysis. For experiments using IκK-16, cells
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were treated with either IκK-16 or DMSO (control) for 1 h after isolation before stimulation
with 100 ng/mL of LPS for an additional 16 h before analysis.
RNA isolation
At the indicated time points, cells were pelleted and stored in 300 μL of lysis buffer at -80˚C.
RNA was extracted using the MirVana miRNA isolation kit (Thermo Fisher Scientific, Wal-
tham, MA). For quality control testing, RNA purity and concentration were measured using a
Nanodrop N-1000 spectrophotometer (Agilent Biosystems, Santa Clara, CA). Samples were
used only when they fulfilled the quality control criteria of 1.8–2.2 purity, based on the ratio of
absorbance at 260 nm and 280 nm (A260/A280 ratio).
Messenger RNA analysis
Complementary DNA (cDNA) was synthesized by reverse transcription (High Capacity
cDNA Reverse Transcription kit, Life Technologies, Foster City, CA). For TNF-α, IL-10,
SOCS1, and SHP1 mRNA quantification, specific primers were used for qRT-PCR, with data
normalized to 18S. For TLR mRNA expression profiling, Taqman1 Array Human Toll Path-
way Core Components profiling plates (Life Technologies, Foster City, CA) were used with a
combination of 18S, GAPDH, and beta2-microglobulin for normalization. A ΔRn (normalized
reporter value) threshold of 0.1 was selected. Taqman1 Universal Master Mix was used with
the StepOne Plus RealTime-PCR-System instrument for qRT-PCR (Applied Biosystems1,
Foster City, CA). Fold changes were calculated using the ΔΔCT method, comparing the
impaired monocyte relative to the naïve monocyte as its control [20].
MicroRNA analysis
For microRNA screening, a total of 1500 ng of diluted RNA was incorporated to create cDNA
by reverse transcription with Megaplex Reverse Transcription Human Pool A v2.1 (Life Tech-
nologies, Foster City, CA). Subsequently, the cDNA was loaded into Taqman1 Low Density
Array cards, divided between 384 wells, for qRT-PCR (human card A, Life Technologies, Fos-
ter City, CA) on a ViiA™ 7 Real-Time PCR System (Applied Biosystems1, Foster City, CA).
RNU6B, RNU44, and RNU48 were used in combination as endogenous controls for data nor-
malization. For single assay microRNA quantification, specific primers were used per micro-
RNA for reverse transcription to create cDNA, with specific primers used for qRT-PCR with
Taqman1 Universal Master Mix. RNU6B was used as an endogenous control for data nor-
malization, and all assays were run in duplicate on a StepOne Plus RealTime-PCR-System
instrument (Applied Biosystems1, Foster City, CA). All microRNA data was analyzed using a
cycle threshold of 0.1 by the ΔΔCT method.[20]
Western blot analysis
Cells were pelleted and lysed using RIPA buffer supplemented with protease and phosphatase
inhibitors (Thermo Scientific, Rockford, IL) and stored at -80˚C until subsequent analysis.
Protein samples were sonicated using a Sonifier 250 (Branson Ultrasonics, Danbury, CT) and
collected by centrifugation at 10,000g for 10 mins. Total protein concentrations were quanti-
fied using a bicinchoninic acid (BCA) protein quantification assay (Thermo Scientific, Rock-
ford, IL). Protein samples of 30 μg were loaded into gradient 4–12% Bis-Tris Plus 12-well gels
in combination with 4X BoltTM LDS sample buffer with 1:100 2-mercaptoethanol. Gels were
run in a BoltTM Mini Gel Tank in Bolt MES SDS running buffer (all from Thermo Scientific,
Waltham, MA) at 180 mV for 45 min, which included a protein size standard (Protein
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Western C Standard, Bio Rad, Hercules, CA). Proteins were transferred to a nitrocellulose
membrane using iBlot Gel Transfer Stacks and an iBlot transfer device (Fisher Scientific,
Hampton, NH). Membranes were blocked with 5% non-fat dried milk in TBS-T for 1 h at
room temperature and incubated overnight with primary antibodies (either rabbit, mouse or
goat anti-human as appropriate) at room temperature. All antibodies were purchased from
Cell Signaling (Danvers, MA), except SOCS1 where antibodies from Abcam were used (Cam-
bridge, UK). Primary antibody concentrations were 1:10,000 for beta-actin and 1:1000 for p65,
vinculin, SOCS1 and SHP1. Membranes were washed in TBS-T before incubation with HRP-
conjugated secondary antibodies (goat anti-rabbit, horse anti-mouse or Donkey anti-goat as
appropriate) at a concentration of 1:1000 for 1 h at room temperature. After further washing,
protein bands were demonstrated with Clarity Western ECL Substrate (Bio-Rad, Hercules,
California), and membranes were imaged using a ChemiDoc MP (Bio Rad, Hercules, CA).
Protein densitometries were measured using ImageLab software (Bio Rad, Hercules, CA). For
quantification, p65 was expressed as relative density units as a ratio over beta-actin as the load-
ing control.
Cytokine analysis
Tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-10 were analyzed in duplicate
using enzyme-linked immunosorbent assays, according to the manufacturer’s instructions
(eBioscience, San Diego, CA). A standard curve from recombinant human cytokines was used
to calculate supernatant cytokine protein concentrations. Sensitivities for the lower limits of
detection were concentrations of 4 pg/mL and 2 pg/mL for TNF-α and IL-10, respectively.
IκK inhibition
IκK-16 was purchased from Sigma Aldrich, St. Louis (MO). Compounds were reconstituted
from stock solution in DMSO as per manufacturer’s instructions and diluted in media to the
appropriate concentrations, resulting in a final DMSO concentration of 0.01%. For the non-
IκK-16 treated control, the equivalent DMSO concentration was used. A dose of 100 nM of
IκK-16 was used unless otherwise specified.
Transfection experiments
Primary human monocytes were transfected using the N-TER Nanoparticle siRNA Transfec-
tion System (Sigma-Aldrich) according to the manufacturer’s instructions. After initial treat-
ment of control (DMSO) or 100 nM IκK-16 for 1 h, monocytes were transfected with miR-155
mimics or antagomirs (Life Technologies, Foster City, CA, USA) at a concentration of 40 nM/
well for 16 h. Control cells were transfected with scramble miRs as a negative control (sham).
After 16 h of transfection, the medium was replaced with fresh medium and the cells were
stimulated with 100 ng/mL LPS for an additional 6 and 24 h. Cells were collected for RNA iso-
lation, whereas supernatants were collected for cytokine measurements. Effective transfection
was confirmed by determining miR-155 levels in isolated RNA by qRT-PCR, using RNU6B as
described, ensuring upregulation of miR-155 cells transfected with mimics and downregula-
tion of miR-155 in cells transfected with antagomirs, relative to sham conditions.
Statistical analysis
Data are shown as mean ± S.E.M. Each donor was used as its own control. Normally distrib-
uted data were analyzed using paired T-tests, and data that were not normally distributed were
analyzed by the Wilcoxon-signed rank test. Data with multiple comparisons were analyzed by
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repeated measures analysis of variance with Tukey’s test for post hoc analysis. Significance was
set at P< 0.050, with the exception of miRNA screening data in which significance was set at
P< 0.010. SigmaPlot was used for presentation of data and for statistical analysis (SyStat Soft-
ware, Inc., Chicago, IL).
Results
Low dose LPS stimulates an initial pro-inflammatory response but with
subsequent NFκB and cytokine suppression
A model of endotoxin tolerance was developed to represent the suppressed immune response.
Monocytes that were treated with 10 ng/mL of LPS demonstrated an increased level of TNF-α
production at 17 h (P< 0.05) (Fig 1A). However, in response to a 100 ng/mL LPS challenge, the
subsequent ability to produce TNF-α was markedly suppressed at 29 h (P< 0.05). Impaired
conditions also demonstrated suppressed IL-10 production in response to the LPS challenge at
29 h (P = 0.04) (Fig 1B). Cell viability was equivalent between naïve and impaired conditions
(S1 Fig).
Cytokine gene expression and NFκB analysis of the impaired monocyte was undertaken
to determine whether suppressed immune responses were due to alterations in canonical
Fig 1. (A) Supernatant TNF-α concentrations and (B) IL-10 concentrations comparing naïve (no LPS pre-treatment) and impaired (10 ng/mL LPS pre-
treatment) conditions. Time points are shown for the end of the pre-treatment prior to the LPS challenge (17 h), and then the response 12 h after the LPS 100
ng/mL challenge (29 h). Levels were determined by ELISA. N = 8. Mean ± S.E.M. are shown. *P < 0.05, paired T-test. Time course of TNF-α (C) and IL-10 (D)
gene expression in the impaired monocyte. Monocytes were treated with 10 ng/mL of LPS given after 1h for a duration of 16 h. At 17 h, cells were washed and
resuspended in fresh media, then received 100 ng/mL of LPS at 17 h. Levels were measured by qRT-PCR, and expressed as fold change (2-ΔΔCT) relative to
the naïve monocyte. Mean ± S.E.M. are shown. N = 4. *P < 0.05. # P = 0.09, paired T-test.
https://doi.org/10.1371/journal.pone.0183987.g001
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signaling in this model of endotoxin tolerance. A time course experiment to examine the gene
expression of TNF-α in the impaired monocyte demonstrated an initial upregulation of TNF-
α mRNA in response to 10 ng/L of LPS, observed maximally at 2 h (P = 0.09) (Fig 1C). How-
ever, after the 100 ng/mL LPS challenge at 17 h, a clear suppression of TNF-α mRNA levels
was be observed maximally at 19 h compared to the naïve control (P < 0.05). Decreased IL-10
gene expression was observed in impaired cells at 17 h (Fig 1D, P< 0.05). Western blot analy-
sis showed that impaired monocytes (10 ng/mL LPS/100 ng/mL LPS) had a decreased concen-
tration of p65 (NFκB) at 60 min after the LPS challenge compared with naïve monocytes
(media only/100 ng/mL LPS) (P< 0.05, Fig 2).
In order to characterize the transcriptional change in the impaired monocyte, alterations in
upstream signaling were studied by profiling TLR gene expression (Fig 3). TNF receptor-asso-
ciated factor 6 (TRAF-6) was significantly downregulated (P< 0.05). Other suppressed genes
that did not reach statistical significance included NFKBIE, CD14, IKBKE, MAPK10, and
REL.
Fig 2. Expression of NFκB (p65) as measured by Western blot analysis. Cells given pre-treatment at 1 h after
isolation until 17 h, and then were washed, suspended in fresh media, and given a further treatment (challenge) for 60
min. Quantitative data are expressed as relative density units, using beta-actin as a loading control. Naïve conditions
(media only / 100 ng/mL LPS) and impaired (10 ng/mL LPS / 100 ng/mL LPS) were compared by paired T-test. N = 6.
Mean ± S.E.M. *P < 0.05.
https://doi.org/10.1371/journal.pone.0183987.g002
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miR-155 is upregulated in the impaired monocyte
Differences in miRNA expression between naïve and impaired monocytes were initially deter-
mined by miRNA screening. Of the 360 miRNAs measured, those that reached statistical sig-
nificance included miR-214 and miR-519e (P< 0.01) (Fig 4). Other miRNAs approaching
significance with log2 fold changes up- or downregulation by greater than 1 included miR-
10a, miR-133b, miR-138, miR-150, miR-155, miR-212, miR-362-3p, miR-518e, and miR-885-
5p.
To address the risk of false-positives from miRNA screening, we undertook single assay
qRT-PCR miRNA confirmation. miRNAs selected for single assay confirmation were chosen
based upon fold changes and statistical significance from screening data, as well as biological
significance. miR-138 and miR-155 remained significantly upregulated when comparing
impaired against naïve conditions at 17 h (Fig 5). miR-212 and miR-519e were also upregu-
lated in the impaired monocyte but did not reach statistical significance (P = 0.09).
IκK-16 decreased miR-155 expression
As a result of IκK inhibition by use of IκK-16 in the presence of 100 ng/mL of LPS, the expres-
sion of miR-155 was reduced compared to cells stimulated in the presence of DMSO only
(P< 0.05) (Fig 6A). Although no differences in SOCS1 expression were observed (Fig 6B),
reciprocal upregulation of SHP1 occurred in monocytes stimulated in the presence of IκK-16
(P< 0.05) (Fig 6C). There was no significant effect of IκK-16 treatment on SOCS1 or SHP1
protein expression at 17 h (Fig 6D and 6E, respectively).
Fig 3. Volcano plot showing toll-like receptor (TLR) gene expression profiles, expressed the impaired
monocyte relative to the naïve monocyte. Monocytes were cultured in media only (naïve) or 10 ng/mL LPS
(impaired) until 17 h and then stimulated with an LPS 100 ng/mL challenge for 2 h. RNA was extracted from cell
pellets, and 44 TLR genes were measured by qRT-PCR. Fold changes (FC) calculated byΔΔCT method are
expressed on the x-axis, with significance (-log10 p-value) demonstrated on the y-axis. Data were normalized to
housekeeper genes 18S, GAPDH, and B2M. Green dots represent genes that are downregulated by a fold
change of 0.66 (equivalent to fold regulation of -1.5). Dots in the blue boxes represent genes that were significantly
dysregulated compared with the naïve monocyte (P < 0.05), paired T-test. N = 4. GAPDH = glyceraldehyde
3-phosphate dehydrogenase. B2M = beta-2 macroglobulin.
https://doi.org/10.1371/journal.pone.0183987.g003
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IκK-16 attenuated the monocyte inflammatory response
In monocytes stimulated with 100 ng/mL of LPS, IκK-16 inhibited the production of both
TNF-α and IL-10 in a dose-dependent fashion (Fig 7A & 7B). A dose of 100 nM was sufficient
to significantly decrease both cytokines (P< 0.05).
Effect of IκK-16 on the cytokine response is partially miR-155 dependent
To determine whether the inhibitory effect of IκK-16 was miR-155 dependent, gain and loss of
miR-155 function experiments were undertaken in the context of IκK-16 treatment. In IκK-16
treated monocytes, transfection of miR-155 mimics increased TNF-α production which
reached significance at 24 h after LPS stimulation (P< 0.05, Fig 8C). In the setting of IκK inhi-
bition, transfection with miR-155 antagomirs lead to decreased TNF-α production at 6 h (Fig
8A) and decreased IL-10 production at 24 h (Fig 8D) (P< 0.05).
Discussion
The immunological response to trauma, major surgery, and sepsis is complex, incompletely
understood, and involves multiple possibly redundant mechanisms of regulation. Recent high-
throughput studies such as those from the Inflammation and the Host Response to Injury proj-
ect [3] have given a deeper insight into the “genomic storm” that occurs after major trauma.
Rather than a specific marker or cytokine that could be targeted by a “magic bullet,” the find-
ings of these studies have shown that it is the magnitude of the immunological response that
dictates the patient outcome. For example, the excessive or prolonged pro-inflammatory
response is one aspect of this response, which increases the risk of infection or death in such
patients [4, 21]. Epigenetic fine-tuning of such dysregulation is becoming increasingly
Fig 4. Volcano plot of miRNA screening of microRNA expression in the impaired monocyte relative to
naïve conditions. Monocytes were cultured in media only (naïve) or 10 ng/mL of LPS until 17 h. RNA was
collected at 17 h, immediately prior to a 100 ng/mL LPS challenge. Data were normalized to housekeeping
genes RNU6B, RNU44, and RNU48. Green dots represent miRNAs that were downregulated by a log2 fold
change of -1.0. Red dots represent miRNA’s that were upregulated by a log2 fold change of +1.0. miRNAs in
the blue boxes represent those that reached statistical significance (P < 0.01), paired T-test. N = 5.
https://doi.org/10.1371/journal.pone.0183987.g004
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recognized as an important part of the pathophysiology in which miRNAs play a key role [13,
17]. miR-155 is an example of a post-transcriptional regulatory mechanism that promotes and
potentiates such an excessive pro-inflammatory response [15]. In studying new therapies for
immunomodulation, we must better understand the molecular mechanisms that underpin its
action in order to increase the successful translation to the patient.
In this study, we used a model of impaired monocyte function that characterizes the initial
pro-inflammatory response and downregulation of HLA-DR expression, but also typifies the
cellular hypo-responsiveness that occurs as a result of excessive stimulation [18, 19]. In our
model, suppressed TNF-α gene expression was observed in impaired cells at 2 h following an
LPS challenge, with decreased TNF-α protein production by 12 h after the LPS challenge. IL-
10 production was also decreased. Indeed, differences in these NFκB-dependent cytokines
were demonstrated in the context of altered NFκB signaling in impaired conditions. We
believe that these findings are broadly in keeping with previous endotoxin tolerance literature.
Our data demonstrated suppressed TRAF-6 and p65 (NFκB) expression in keeping with a sup-
pressed cytokine response following subsequent LPS exposure. miRNA confirmation demon-
strated that miR-155 and miR-138 were significantly elevated in the impaired monocyte. Due
to the important regulatory role as well as the clinical relevance, we focused on miR-155. The
data demonstrated that the upregulation of miR-155 in response to LPS was dependent on the
IκK-NFκB pathway. Modulation of the response to a stimulus with IκK-16, a novel specific
inhibitor of IκK, was not only capable of modulating miR-155 expression, but also influenced
the gene expression of the downstream target of miR-155, SHP1, in a reciprocal fashion. In
order to determine whether the inhibitory effect of IκK-16 was miR-155-dependent or not, we
undertook gain- and loss-of-function experiments in the setting of IκK-16 inhibition. Indeed,
the re-introduction of miR-155 lead to an increase in TNF-α but not in IL-10 production. Con-
versely, a further decrease in miR-155 via antagomirs decreased both TNF-α and IL-10 levels.
These findings suggest that IκK-16 treatment can modulate the excessive pro-inflammatory
Fig 5. Verification of miRNA differences in the impaired monocyte relative to naïve conditions at 17 h.
The most significant miRNAs selected from screening were used for single assay qRT-PCR confirmation.
Data were normalized to RNU6B. N = 8. Mean ± S.E.M. *P < 0.05, paired T-test.
https://doi.org/10.1371/journal.pone.0183987.g005
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response, such as that observed in the “high risk” patient, through manipulation of miR-155.
Replenishing pools of miR-155 did not completely restore TNF-α levels to that of the non-IκK-
16 treated cells. This may indicate that IκK-16 acts through miR-155-independent mechanisms,
but may also reflect the dominant effect of IκK inhibition. Another important miRNA, miR-
146a, has frequently been found to be associated with endotoxin tolerance [22, 23]. In our
screening results, miR-146a appeared to be elevated but did not reach statistical significance.
However, we found that a key target of miRNA-146a in toll-like receptor signaling, TRAF-6,
was significantly suppressed.
Our results are consistent with previous reports demonstrating an upregulation of miR-155
and miR-138 in response to stimuli such as LPS [24–26]. miR-138 is known to target SIRT1
and HIF-1α, which are two genes that have previously been associated with impaired mono-
cyte responses [27, 28] and could plausibly contribute to the pathogenesis of this form of
immunosuppression [29]. This may be an interesting area for future research. The focus of our
Fig 6. Effect of IκK-16 on miR-155 (A), SOCS1 (B) and SHP1 (C) expression. Monocytes were cultured with 100 nM of IκK-16 or
DMSO (control) for 1 h and then 100 ng/mL of LPS was given for 17 h. Levels of miR-155, SOCS1, and SHP1 expression in IκK-16
treated monocytes are expressed as fold change relative to the DMSO (control) monocytes, as determined by qRT-PCR. MiRNA
data were normalized to RNU6B, and mRNA data were normalized to 18S. Mean ± S.E.M. N = 6. * P<0.05, paired T-test. Western
blot was similarly used determine protein levels at 17 h for SOCS1 (D) and SHP1 (E), with vinculin and beta-actin used as loading
controls, respectively.
https://doi.org/10.1371/journal.pone.0183987.g006
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group has been on studying the role of miR-155 in the monocyte inflammatory response,
which was significantly dysregulated miRNA as per our single assay verification experiments.
miR-155 has a very complex role through its numerous important gene targets. Previous
Fig 7. Effect of IκK-16 on cytokine production. Monocytes were treated with DMSO (control) or IκK-16 for
1 h and then stimulated with 100 ng/mL of LPS for an additional 16 h. Supernatant levels of (A) TNF-α and (B)
IL-10 were measured by ELISA at 17 h. Mean ± S.E.M. are shown. N = 4. *P < 0.05 vs. DMSO only. †P = 0.06
vs. DMSO only. #P<0.05 vs. 1 nM. ‡P = 0.08 vs. 1 nM. Repeated Measures ANOVA with Tukey test for post-
hoc analysis.
https://doi.org/10.1371/journal.pone.0183987.g007
Fig 8. Effect of miR-155 on cytokine production. Monocytes were treated either with DMSO (as control) or 100 nM IκK-16 for 1 h and then transfected with
scrambled RNA (sham) or miR-155 mimics or antagomirs for 16 h. Cells were then stimulated with 100 ng/mL of LPS for 6 (A & B) and 24 h (C & D).
Supernatant protein levels of TNF-α and IL-10 were determined by ELISA. N = 4, Paired t-test. * P < 0.05. † p = 0.050. ‡ p = 0.090.
https://doi.org/10.1371/journal.pone.0183987.g008
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reports have shown that p65 binds to the promoter region of the miR-155 gene, and that NFκB
inhibition prevents miR-155 upregulation [30],[24], Various reports have shown that miR-155
promotes and potentiates the pro-inflammatory response by suppressing SOCS1 and SHP1,
thus increasing the pro-inflammatory cytokine response such as TNF-α [24]. Previous reports
from our group, along with others, have shown the reciprocal relationship between miR-155
and SOCS1 and SHP1 [16, 31, 32]. The findings of elevated miR-155 in response to the low
dose 10 ng/L of LPS at 17 h correlates with elevated TNF-α levels at this time point. However,
miR-155 also targets p65, [33] the active subunit of the NFκB pathway, as well as MyD88 and
IκK-ε [6, 34]. In this report, we found a correlation between elevated miR-155 and decreased
p65. Through delayed suppression of these pro-inflammatory pathways as well as cross-toler-
ance from the initial rise in TNF-α, miR-155 may also contribute to the impaired monocyte
responses [34–36]. Indeed, elevated miR-155 has been reported in patients diagnosed with sep-
sis [37]. miR-155 may also play a role as a biomarker in patients who have both an excessive
pro-inflammatory response and subsequent monocyte impairment that occurs as a result.
It should be noted that inhibition of miR-155 improves outcomes in experimental peritoni-
tis [38, 39]. miRNAs have not yet been successfully used directly as a therapeutic modality in
humans; however, some miRNAs are under investigation [40]. What is more feasible is to
understand the molecular mechanisms of existing and future therapies by studying their effects
on miRNA expression.
Excessive activation of the NFκB pathway in monocytes from surgical patients is associated
with an increased risk of postoperative systemic inflammatory response syndrome [41]. There
are literally thousands of genes that are up-and downregulated in association with excessive
stimulation [42]. However, previous attempts to therapeutically target specific markers or
products of excessive inflammation, such as IL-1β and TNF-α, have failed to improve mortal-
ity rates [7]. A more feasible approach could be to focus upstream of the cytokines themselves
and target pathways such as NFκB that govern immune responses to “tune down” this so-
called cytokine storm. IκK-16 is a selective blocker of inhibitor of kappa-B kinase (IκK). Its
application in a mouse model of peritonitis attenuated NFκB activation and resulted in
decreased multiple organ dysfunction [9]. The same group treated a rat model of hemorrhagic
shock with IκK-16, which resulted in decreased circulating cytokines and improved markers
of organ function. Most recently, IκK-16 treatment was given to mice with unilateral nephrec-
tomy and peritonitis as a model of chronic kidney disease and sepsis [12]. Decreased cardiac
dysfunction and lung inflammation was observed. However, by inhibiting the inflammatory
response, one must understand the underlying mechanisms to avoid harmful suppression of
the immune response. Promisingly, a murine study of acute lung injury demonstrated that
transient IκK inhibition did not compromise bacterial host defense mechanisms [43].
Our results demonstrate that IκK-16 decreases the cytokine levels in primary human mono-
cytes, supporting the findings from these pre-clinical models. In addition, we have shown that
IκK-16 decreases miR-155, an important regulator of the immune response, which appears to
be one mechanism through which limiting excessive inflammation may be achieved.
This study does have limitations. The process of monocyte isolation is mildly stimulatory to
the cells; therefore, the additional pre-treatment of 10 ng/mL of LPS provided only modest
fold changes in miRNA expression between conditions. Due to the dynamic nature of intracel-
lular miRNA and mRNA expression during the inflammatory response, we cannot exclude
other miRNAs that may be dysregulated at different time points. There are various NFκB
inhibitors that have been previously tested in animal models of sepsis. IκK-16 targets IκK-α/β
which is proximal in the NFκB pathway. Given the complex cross-talk between different sig-
naling pathways, there may be some benefit in dampening the amplitude of the signal earlier
in the pathway compared with agents specifically targeting NFκB. The potential benefits of
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IκK-16 include that it is not toxic to human cells and has shown benefit in in-vivo sepsis mod-
els. Other inhibitors of IκK may also prove to be effective in limiting the magnitude of the
immune response.
In summary, we have shown that impaired monocytes express elevated levels of miR-155
and miR-138 and are associated with decreased p65 and TNF-α production. Our data demon-
strate that miR-155 expression is IκK-dependent, and that IκK-16 is a novel treatment that
appears to modulate the human monocyte inflammatory response through attenuation of
miR-155. Understanding the mechanistic effects of IκK-16 on the monocyte inflammatory
response may help in translating this potential therapy to the bedside of the acutely unwell
patient with an excessive inflammatory response.
Supporting information
S1 Fig. Cell viability is equivalent between naïve and impaired conditions. Cell viability was
determined by standard microscopy with Trypan Blue staining. Rates of monocyte viability
were equivalent between naïve and impaired conditions. N = 7. N.S., not significant, paired T-
test.
(TIF)
S2 Fig. Effect of IκK-16 on monocyte viability. Cultured primary monocytes were incubated
with increasing doses of IκK16 in the presence of 100 ng/mL of LPS for 16 h. Cells were stained
with Trypan Blue and manually counted to determine viability (n = 4).
(TIF)
S1 Table. Supplemental individual donor data.
(XLSX)
Acknowledgments
This work was funded by the John W. Price and Barbara Thruston Atwood Price Trust, by the
James and Emmeline Ferguson Research Fellowship Trust, by the Dizney Family Foundation,
and by the Mary K. Oxley Foundation. We would like to acknowledge the use of equipment
from Jason Smith, MD, PhD.
No competing financial interests exist.
Author Contributions
Conceptualization: Norman James Galbraith.
Data curation: Norman James Galbraith.
Formal analysis: Norman James Galbraith.
Funding acquisition: Hiram C. Polk.
Investigation: Norman James Galbraith.
Methodology: Norman James Galbraith, James Burton, Mathew Brady Ekman, Joseph Ken-
ney, Samuel Patterson Walker, Stephen Manek, Campbell Bishop, Sarah Appel Gardner.
Resources: Norman James Galbraith, Sarah Appel Gardner.
Supervision: Norman James Galbraith, Sarah Appel Gardner, Hiram C. Polk.
Writing – original draft: Norman James Galbraith, Hiram C. Polk.
Writing – review & editing: Norman James Galbraith, Jane Victoria Carter, Hiram C. Polk.
IκK-16 decreases monocyte miR-155 expression
PLOS ONE | https://doi.org/10.1371/journal.pone.0183987 September 14, 2017 13 / 16
References
1. Polinder S, Haagsma JA, Toet H, van Beeck EF. Epidemiological burden of minor, major and fatal
trauma in a national injury pyramid. The British journal of surgery. 2012; 99 Suppl 1:114–21. Epub
2012/03/28. https://doi.org/10.1002/bjs.7708 PMID: 22441864.
2. Polk HC Jr., George CD, Wellhausen SR, Cost K, Davidson PR, Regan MP, et al. A systematic study of
host defense processes in badly injured patients. Annals of surgery. 1986; 204(3):282–99. PMID:
3019260; PubMed Central PMCID: PMCPMC1251278.
3. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, et al. A genomic storm in critically
injured humans. J Exp Med. 2011; 208(13):2581–90. https://doi.org/10.1084/jem.20111354 PMID:
22110166; PubMed Central PMCID: PMCPMC3244029.
4. Demetriades D, Kimbrell B, Salim A, Velmahos G, Rhee P, Preston C, et al. Trauma deaths in a mature
urban trauma system: is "trimodal" distribution a valid concept? J Am Coll Surg. 2005; 201(3):343–8.
https://doi.org/10.1016/j.jamcollsurg.2005.05.003 PMID: 16125066.
5. Galbraith N, Walker S, Galandiuk S, Gardner S, Polk HC Jr. The Significance and Challenges of Mono-
cyte Impairment: For the Ill Patient and the Surgeon. Surgical infections. 2016; 17(3):303–12. Epub
2016/03/10. https://doi.org/10.1089/sur.2015.245 PMID: 26958709.
6. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical signifi-
cance. Trends Immunol. 2009; 30(10):475–87. https://doi.org/10.1016/j.it.2009.07.009 PMID:
19781994.
7. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014; 20(4):195–203. https://doi.
org/10.1016/j.molmed.2014.01.007 PMID: 24581450.
8. Galbraith N, Walker S, Carter J, Polk HC Jr. Past, Present, and Future of Augmentation of Monocyte
Function in the Surgical Patient. Surgical infections. 2016. Epub 2016/06/17. https://doi.org/10.1089/
sur.2016.014 PMID: 27309382.
9. Coldewey SM, Rogazzo M, Collino M, Patel NS, Thiemermann C. Inhibition of IkappaB kinase reduces
the multiple organ dysfunction caused by sepsis in the mouse. Disease models & mechanisms. 2013; 6
(4):1031–42. Epub 2013/05/08. https://doi.org/10.1242/dmm.012435 PMID: 23649820; PubMed Cen-
tral PMCID: PMCPmc3701222.
10. Sordi R, Chiazza F, Johnson FL, Patel NS, Brohi K, Collino M, et al. Inhibition of IkappaB Kinase Attenu-
ates the Organ Injury and Dysfunction Associated with Hemorrhagic Shock. Molecular medicine (Cam-
bridge, Mass). 2015; 21:563–75. Epub 2015/06/24. https://doi.org/10.2119/molmed.2015.00049 PMID:
26101953; PubMed Central PMCID: PMCPmc4607620.
11. Shu YS, Tao W, Miao QB, Zhu YB, Yang YF. Improvement of ventilation-induced lung injury in a rodent
model by inhibition of inhibitory kappaB kinase. The journal of trauma and acute care surgery. 2014; 76
(6):1417–24. Epub 2014/05/24. https://doi.org/10.1097/TA.0000000000000229 PMID: 24854310.
12. Chen J, Kieswich JE, Chiazza F, Moyes AJ, Gobbetti T, Purvis GS, et al. IkappaB Kinase Inhibitor
Attenuates Sepsis-Induced Cardiac Dysfunction in CKD. Journal of the American Society of Nephrol-
ogy: JASN. 2016. Epub 2016/05/08. https://doi.org/10.1681/asn.2015060670 PMID: 27153924.
13. Billeter AT, Druen D, Kanaan ZM, Polk HC Jr. MicroRNAs: new helpers for surgeons? Surgery. 2012;
151(1):1–5. Epub 2011/10/25. https://doi.org/10.1016/j.surg.2011.08.006 PMID: 22019341.
14. Carter JV, Roberts HL, Pan J, Rice JD, Burton JF, Galbraith NJ, et al. A Highly Predictive Model for
Diagnosis of Colorectal Neoplasms Using Plasma MicroRNA: Improving Specificity and Sensitivity.
Annals of surgery. 2016; 264(4):575–84. Epub 2016/07/30. https://doi.org/10.1097/SLA.
0000000000001873 PMID: 27471839; PubMed Central PMCID: PMCPmc5115272.
15. Elton TS, Selemon H, Elton SM, Parinandi NL. Regulation of the MIR155 host gene in physiological and
pathological processes. Gene. 2013; 532(1):1–12. Epub 2012/12/19. https://doi.org/10.1016/j.gene.
2012.12.009 PMID: 23246696.
16. Billeter AT, Hellmann J, Roberts H, Druen D, Gardner SA, Sarojini H, et al. MicroRNA-155 potentiates
the inflammatory response in hypothermia by suppressing IL-10 production. FASEB journal: official
publication of the Federation of American Societies for Experimental Biology. 2014; 28(12):5322–36.
https://doi.org/10.1096/fj.14-258335 PMID: 25231976; PubMed Central PMCID: PMCPMC4232280.
17. O’Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annual review
of immunology. 2012; 30:295–312. Epub 2012/01/10. https://doi.org/10.1146/annurev-immunol-
020711-075013 PMID: 22224773.
18. Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte
reprogramming in sepsis. Critical care (London, England). 2006; 10(5):233. https://doi.org/10.1186/
cc5055 PMID: 17044947; PubMed Central PMCID: PMCPMC1751079.
19. West MA, Heagy W. Endotoxin tolerance: a review. Critical care medicine. 2002; 30(1 Suppl):S64–73.
Epub 2002/01/10. PMID: 11782563.
IκK-16 decreases monocyte miR-155 expression
PLOS ONE | https://doi.org/10.1371/journal.pone.0183987 September 14, 2017 14 / 16
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR
and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif). 2001; 25(4):402–8. Epub 2002/02/16.
https://doi.org/10.1006/meth.2001.1262 PMID: 11846609.
21. Almahmoud K, Namas RA, Abdul-Malak O, Zaaqoq AM, Zamora R, Zuckerbraun BS, et al. Impact of
Injury Severity on Dynamic Inflammation Networks Following Blunt Trauma. Shock (Augusta, Ga).
2015; 44(2):101–9. Epub 2015/05/27. https://doi.org/10.1097/SHK.0000000000000395 PMID:
26009819; PubMed Central PMCID: PMCPmc4504837.
22. Zhou J, Chaudhry H, Zhong Y, Ali MM, Perkins LA, Owens WB, et al. Dysregulation in microRNA
expression in peripheral blood mononuclear cells of sepsis patients is associated with immunopathol-
ogy. Cytokine. 2015; 71(1):89–100. https://doi.org/10.1016/j.cyto.2014.09.003 PMID: 25265569;
PubMed Central PMCID: PMCPMC4252591.
23. Nahid MA, Pauley KM, Satoh M, Chan EK. miR-146a is critical for endotoxin-induced tolerance: IMPLI-
CATION IN INNATE IMMUNITY. The Journal of biological chemistry. 2009; 284(50):34590–9. Epub
2009/10/21. https://doi.org/10.1074/jbc.M109.056317 PMID: 19840932; PubMed Central PMCID:
PMCPmc2787321.
24. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, et al. Modulation of miR-155 and miR-
125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the
response to endotoxin shock. Journal of immunology (Baltimore, Md: 1950). 2007; 179(8):5082–9.
Epub 2007/10/04. PMID: 17911593.
25. Zhou X, Luan X, Chen Z, Francis M, Gopinathan G, Li W, et al. MicroRNA-138 Inhibits Periodontal Pro-
genitor Differentiation under Inflammatory Conditions. Journal of dental research. 2016; 95(2):230–7.
Epub 2015/11/01. https://doi.org/10.1177/0022034515613043 PMID: 26518300; PubMed Central
PMCID: PMCPmc4720956.
26. Guo K, Yang Y, Qiu J, Kan Q, Zhou XG, Zhou XY. The expression profile of microRNAs in wistar rats
with lipopolysaccharide-induced periventricular leukomalacia. Journal of molecular neuroscience: MN.
2013; 51(3):941–9. Epub 2013/01/29. https://doi.org/10.1007/s12031-013-9958-y PMID: 23354881.
27. Vachharajani VT, Liu T, Brown CM, Wang X, Buechler NL, Wells JD, et al. SIRT1 inhibition during the
hypoinflammatory phenotype of sepsis enhances immunity and improves outcome. Journal of leuko-
cyte biology. 2014; 96(5):785–96. Epub 2014/07/09. https://doi.org/10.1189/jlb.3MA0114-034RR
PMID: 25001863; PubMed Central PMCID: PMCPmc4197566.
28. Frede S, Stockmann C, Winning S, Freitag P, Fandrey J. Hypoxia-inducible factor (HIF) 1alpha accu-
mulation and HIF target gene expression are impaired after induction of endotoxin tolerance. Journal of
immunology (Baltimore, Md: 1950). 2009; 182(10):6470–6. Epub 2009/05/06. https://doi.org/10.4049/
jimmunol.0802378 PMID: 19414801.
29. Sen A, Most P, Peppel K. Induction of microRNA-138 by pro-inflammatory cytokines causes endothelial
cell dysfunction. FEBS letters. 2014; 588(6):906–14. Epub 2014/02/04. https://doi.org/10.1016/j.
febslet.2014.01.033 PMID: 24486907; PubMed Central PMCID: PMCPmc3975049.
30. Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein-Barr virus latent membrane pro-
tein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic acids research.
2008; 36(20):6608–19. Epub 2008/10/23. https://doi.org/10.1093/nar/gkn666 PMID: 18940871;
PubMed Central PMCID: PMCPmc2582607.
31. Billeter AT, Rice J, Druen D, Sklare S, Walker S, Gardner SA, et al. Warming to 39 degrees C but Not to
37 degrees C Ameliorates the Effects on the Monocyte Response by Hypothermia. Annals of surgery.
2016; 263(3):601–7. Epub 2015/02/27. https://doi.org/10.1097/SLA.0000000000001175 PMID:
25719808.
32. Lu C, Huang X, Zhang X, Roensch K, Cao Q, Nakayama KI, et al. miR-221 and miR-155 regulate
human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1,
and SOCS-1. Blood. 2011; 117(16):4293–303. Epub 2011/03/01. https://doi.org/10.1182/blood-2010-
12-322503 PMID: 21355095; PubMed Central PMCID: PMCPmc3087479.
33. Wu XY, Fan WD, Fang R, Wu GF. Regulation of microRNA-155 in endothelial inflammation by targeting
nuclear factor (NF)-kappaB P65. Journal of cellular biochemistry. 2014; 115(11):1928–36. Epub 2014/
06/07. https://doi.org/10.1002/jcb.24864 PMID: 24905663.
34. Nahid MA, Satoh M, Chan EK. MicroRNA in TLR signaling and endotoxin tolerance. Cellular & molecu-
lar immunology. 2011; 8(5):388–403. Epub 2011/08/09. https://doi.org/10.1038/cmi.2011.26 PMID:
21822296; PubMed Central PMCID: PMCPmc3618661.
35. Ceppi M, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA, et al. MicroRNA-155 modu-
lates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proceed-
ings of the National Academy of Sciences of the United States of America. 2009; 106(8):2735–40. Epub
2009/02/06. https://doi.org/10.1073/pnas.0811073106 PMID: 19193853; PubMed Central PMCID:
PMCPmc2650335.
IκK-16 decreases monocyte miR-155 expression
PLOS ONE | https://doi.org/10.1371/journal.pone.0183987 September 14, 2017 15 / 16
36. Park SH, Park-Min KH, Chen J, Hu X, Ivashkiv LB. Tumor necrosis factor induces GSK3 kinase-medi-
ated cross-tolerance to endotoxin in macrophages. Nature immunology. 2011; 12(7):607–15. Epub
2011/05/24. https://doi.org/10.1038/ni.2043 PMID: 21602809; PubMed Central PMCID:
PMCPmc3258532.
37. Liu J, Shi K, Chen M, Xu L, Hong J, Hu B, et al. Elevated miR-155 expression induces immunosuppres-
sion via CD39(+) regulatory T-cells in sepsis patient. International journal of infectious diseases: IJID:
official publication of the International Society for Infectious Diseases. 2015; 40:135–41. Epub 2015/10/
04. https://doi.org/10.1016/j.ijid.2015.09.016 PMID: 26433115.
38. Lv X, Zhang Y, Cui Y, Ren Y, Li R, Rong Q. Inhibition of microRNA155 relieves sepsisinduced liver
injury through inactivating the JAK/STAT pathway. Molecular medicine reports. 2015; 12(4):6013–8.
Epub 2015/08/08. https://doi.org/10.3892/mmr.2015.4188 PMID: 26251957.
39. Wang H, Bei Y, Huang P, Zhou Q, Shi J, Sun Q, et al. Inhibition of miR-155 Protects Against LPS-
induced Cardiac Dysfunction and Apoptosis in Mice. Molecular therapy Nucleic acids. 2016; 5(10):
e374. Epub 2016/10/12. https://doi.org/10.1038/mtna.2016.80 PMID: 27727247; PubMed Central
PMCID: PMCPmc5095684.
40. Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA therapeutics: Discovering
novel targets and developing specific therapy. Perspectives in clinical research. 2016; 7(2):68–74.
Epub 2016/05/04. https://doi.org/10.4103/2229-3485.179431 PMID: 27141472; PubMed Central
PMCID: PMCPmc4840794.
41. Lahiri R, Derwa Y, Bashir Z, Giles E, Torrance HD, Owen HC, et al. Systemic Inflammatory Response
Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5. Annals
of surgery. 2016; 263(5):1028–37. Epub 2015/05/29. https://doi.org/10.1097/SLA.0000000000001248
PMID: 26020106.
42. Laudanski K, Miller-Graziano C, Xiao W, Mindrinos MN, Richards DR, De A, et al. Cell-specific expres-
sion and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways.
Proceedings of the National Academy of Sciences of the United States of America. 2006; 103
(42):15564–9. https://doi.org/10.1073/pnas.0607028103 PMID: 17032758; PubMed Central PMCID:
PMCPMC1592643.
43. Li H, Han W, Polosukhin V, Yull FE, Segal BH, Xie CM, et al. NF-kappaB inhibition after cecal ligation
and puncture reduces sepsis-associated lung injury without altering bacterial host defense. Mediators
of inflammation. 2013; 2013:503213. Epub 2013/12/19. https://doi.org/10.1155/2013/503213 PMID:
24347827; PubMed Central PMCID: PMCPmc3852536.
IκK-16 decreases monocyte miR-155 expression
PLOS ONE | https://doi.org/10.1371/journal.pone.0183987 September 14, 2017 16 / 16
